Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies
Page 5 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.
- Study Conducted Among Patients With CMLCompletedNCT05476562
- TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsActive, not recruitingNCT05434312Phase 1
- Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
- Special Drug Use-results Surveillance of Scemblix TabletsCompletedNCT05421091
- Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CMLTerminatedNCT05413915Phase 3
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
- Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib TreatmentCompletedNCT05387330
- Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CMLStatus unknownNCT05376852Phase 2
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesActive, not recruitingNCT05362773Phase 1
- MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
- A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic MalignanciesWithdrawnNCT05201183Phase 1/2
- Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic MalignancyStatus unknownNCT05154474
- FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid LeukemiaStatus unknownNCT05152537
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05143840Phase 2
- A Study for PRO of CML in Real WordStatus unknownNCT05092048
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
- Myeloid Mutations Register in R/R CMLStatus unknownNCT05080829Not applicable
- Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem CellsStatus unknownNCT04991532
- Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid MalignanciesCompletedNCT04943757Phase 2
- The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP PatientsStatus unknownNCT04933526Phase 4
- A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)CompletedNCT04925141Phase 4
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Value of Using Pioglitazone in Chronic Myeloid Leukemia TreatmentCompletedNCT04883125Phase 2
- TIGIT in Patients With Chronic Myeloid LeukemiaStatus unknownNCT04818619
- IIT PH1 KDS-1001 in Patients With CMLWithdrawnNCT04808115Phase 1
- Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2
- A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid LeukemiaCompletedNCT04694820Not applicable
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompletedNCT04681105Phase 1
- Flumatinib in CML-CP Patients With Ph+ Post Imatinib FailureStatus unknownNCT04677439Phase 4
- Innate T Cells and TKI DiscontinuationActive, not recruitingNCT04645706
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationActive, not recruitingNCT04626024Phase 2
- Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI DiscontinuationCompletedNCT04621851
- A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase InhibitorsCompletedNCT04605211Not applicable
- Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of LifeCompletedNCT04595955Not applicable
- Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer MedicationsTerminatedNCT04595851Not applicable
- Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid LeukemiaStatus unknownNCT04591197
- A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
- Nilotinib, for Patients With CML-CP or CML-APNo longer availableNCT04518644
- HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell TransplantationWithdrawnNCT04464889Phase 1
- DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic CancerCompletedNCT04282343Not applicable
- CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
- Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid LeukemiaActive, not recruitingNCT04258943Phase 1/2
- The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationCompletedNCT04233346Phase 2
- Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
- Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell TransplantActive, not recruitingNCT04167683
- Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)CompletedNCT04160546Phase 2
- CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT04156256Early Phase 1
- Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CPStatus unknownNCT04155411Phase 4
- Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia PatientsStatus unknownNCT04150471
- Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaActive, not recruitingNCT04147533Phase 2
- The Absorption, Metabolism and Excretion of [14C] HQP1351 in HumansCompletedNCT04126707Phase 1
- A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT04126681Phase 2
- Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular ResponseStatus unknownNCT04104035
- A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life SettingCompletedNCT04089839
- Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseActive, not recruitingNCT04070443Phase 2
- Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)CompletedNCT04048564
- Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid LeukemiaStatus unknownNCT04043676Phase 2
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- Collect and Assess Tissue Samples From Subjects With Hematologic MalignancyCompletedNCT04014764
- Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesActive, not recruitingNCT04013685Phase 1
- Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.CompletedNCT03996096
- Nilotinib for First-line Newly Diagnosed CML-CP PatientsStatus unknownNCT03942094Phase 3
- Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any DoseActive, not recruitingNCT03933852
- Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase InhibitorStatus unknownNCT03907670
- Frontline Asciminib Combination in Chronic Phase CMLActive, not recruitingNCT03906292Phase 2
- Precision Dosing of Tyrosine Kinase Inhibitors in CML PatientsCompletedNCT03885830
- A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationStatus unknownNCT03883100Phase 2
- Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid LeukemiaCompletedNCT03882281Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminatedNCT03874858Phase 2
- Ex Vivo Drug Sensitivity Testing and Mutation ProfilingCompletedNCT03860376
- Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From DiagnosisCompletedNCT03831776Phase 2
- Study in Patients With Chronic LeukemiaTerminatedNCT03807479Phase 2
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1
- CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT03795779Early Phase 1
- Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortalityTerminatedNCT03746054Phase 3
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2
- Iclusig PMS in CML or Ph+ALL PatientsStatus unknownNCT03709017
- IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCTTerminatedNCT03696537Phase 1
- Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in BelgiumCompletedNCT03678454
- CALLS: CML and Ph+ALL Low Level Mutation Prevalence SurveyCompletedNCT03647215
- The Hong Kong CML RegistryStatus unknownNCT03625583
- Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaCompletedNCT03625388Phase 2
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
- Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsActive, not recruitingNCT03610971Phase 2
- Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
- Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI TreatmentStatus unknownNCT03573596Phase 2
- Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov ApproachCompletedNCT03540654
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
- Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML PatientsStatus unknownNCT03515018Phase 3
- Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT03509896
- Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
- Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in EgyptCompletedNCT03454503
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnNCT03438344Phase 2
- Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)CompletedNCT03421626
- Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic MalignanciesWithdrawnNCT03414450Phase 1
- Sleep Assessment in CMLStatus unknownNCT03353558
- Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid LeukemiaStatus unknownNCT03348033Phase 1/2
- Efficacy and Safety of Nilotinib in CML-CPCompletedNCT03332511Phase 4